Published in Prostate on February 01, 2008
Cancer epigenetics: tumor heterogeneity, plasticity of stem-like states, and drug resistance. Mol Cell (2014) 1.99
Evidence for field cancerization of the prostate. Prostate (2009) 1.86
Using the epigenetic field defect to detect prostate cancer in biopsy negative patients. J Urol (2012) 1.60
MicroRNA-145 is regulated by DNA methylation and p53 gene mutation in prostate cancer. Carcinogenesis (2011) 1.51
Discovery of novel hypermethylated genes in prostate cancer using genomic CpG island microarrays. PLoS One (2009) 1.28
Evaluation of GSTP1 and APC methylation as indicators for repeat biopsy in a high-risk cohort of men with negative initial prostate biopsies. BJU Int (2011) 1.19
Insulin-like growth factor-2 (IGF2) loss of imprinting marks a field defect within human prostates containing cancer. Prostate (2011) 1.12
Clinical validation of an epigenetic assay to predict negative histopathological results in repeat prostate biopsies. J Urol (2014) 1.10
Tumor focality in prostate cancer: implications for focal therapy. Nat Rev Clin Oncol (2010) 1.09
Differential gene expression in benign prostate epithelium of men with and without prostate cancer: evidence for a prostate cancer field effect. Clin Cancer Res (2010) 1.09
Markers of field cancerization: proposed clinical applications in prostate biopsies. Prostate Cancer (2012) 1.00
Spatially resolved optical and ultrastructural properties of colorectal and pancreatic field carcinogenesis observed by inverse spectroscopic optical coherence tomography. J Biomed Opt (2014) 0.95
A novel gene signature for molecular diagnosis of human prostate cancer by RT-qPCR. PLoS One (2008) 0.94
A tissue biopsy-based epigenetic multiplex PCR assay for prostate cancer detection. BMC Urol (2012) 0.94
Clinical utility of prostate carcinoma molecular diagnostic tests. Rev Urol (2008) 0.93
Applicability of HIN-1, MGMT and RASSF1A promoter methylation as biomarkers for detecting field cancerization in breast cancer. Breast Cancer Res (2015) 0.91
Methylation of APC and GSTP1 in non-neoplastic tissue adjacent to prostate tumour and mortality from prostate cancer. PLoS One (2013) 0.90
Methylation of the RARB gene increases prostate cancer risk in black Americans. J Urol (2013) 0.86
ID4 is frequently downregulated and partially hypermethylated in prostate cancer. World J Urol (2011) 0.84
Budget impact model: epigenetic assay can help avoid unnecessary repeated prostate biopsies and reduce healthcare spending. Am Health Drug Benefits (2013) 0.83
Identification of FISH biomarkers to detect chromosome abnormalities associated with prostate adenocarcinoma in tumour and field effect environment. BMC Cancer (2014) 0.83
Reduced Rate of Repeated Prostate Biopsies Observed in ConfirmMDx Clinical Utility Field Study. Am Health Drug Benefits (2014) 0.83
Current prostate biopsy protocols cannot reliably identify patients for focal therapy: correlation of low-risk prostate cancer on biopsy with radical prostatectomy findings. Int J Clin Exp Pathol (2010) 0.81
Nuclear iASPP may facilitate prostate cancer progression. Cell Death Dis (2014) 0.79
3.4 kb mitochondrial genome deletion serves as a surrogate predictive biomarker for prostate cancer in histopathologically benign biopsy cores. Can Urol Assoc J (2010) 0.79
Rectal Optical Markers for In Vivo Risk Stratification of Premalignant Colorectal Lesions. Clin Cancer Res (2015) 0.79
A panel of DNA methylation markers reveals extensive methylation in histologically benign prostate biopsy cores from cancer patients. Biomark Res (2014) 0.78
Methylation in benign prostate and risk of disease progression in men subsequently diagnosed with prostate cancer. Int J Cancer (2016) 0.78
Methylome-wide Sequencing Detects DNA Hypermethylation Distinguishing Indolent from Aggressive Prostate Cancer. Cell Rep (2015) 0.77
Biomarkers for prostate cancer: present challenges and future opportunities. Future Sci OA (2015) 0.77
HES5 silencing is an early and recurrent change in prostate tumourigenesis. Endocr Relat Cancer (2015) 0.76
Heterogeneous patterns of DNA methylation-based field effects in histologically normal prostate tissue from cancer patients. Sci Rep (2017) 0.75
CLINICAL EVALUATION OF AN EPIGENETIC ASSAY TO PREDICT MISSED CANCER IN PROSTATE BIOPSY SPECIMENS. Trans Am Clin Climatol Assoc (2016) 0.75
Hypermethylation of CDKN2A exon 2 in tumor, tumor-adjacent and tumor-distant tissues from breast cancer patients. BMC Cancer (2017) 0.75
Clinically relevant genetic characterization of prostate tumors: how close are we to the goal? Korean J Urol (2015) 0.75
Novel genes associated with malignant melanoma but not benign melanocytic lesions. Clin Cancer Res (2005) 3.30
Microglia/macrophage polarization dynamics reveal novel mechanism of injury expansion after focal cerebral ischemia. Stroke (2012) 2.88
Identification of differentially expressed genes in pancreatic cancer cells using cDNA microarray. Cancer Res (2002) 2.55
An assessment of Motorola CodeLink microarray performance for gene expression profiling applications. Nucleic Acids Res (2002) 2.37
SNPstream UHT: ultra-high throughput SNP genotyping for pharmacogenomics and drug discovery. Biotechniques (2002) 2.25
A new rabbit monoclonal antibody (4B5) for the immunohistochemical (IHC) determination of the HER2 status in breast cancer: comparison with CB11, fluorescence in situ hybridization (FISH), and interlaboratory reproducibility. Appl Immunohistochem Mol Morphol (2007) 2.15
Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer. Clin Cancer Res (2003) 2.11
Acetylation of p53 at lysine 373/382 by the histone deacetylase inhibitor depsipeptide induces expression of p21(Waf1/Cip1). Mol Cell Biol (2006) 2.02
Systemic dissemination of Clostridium difficile toxins A and B is associated with severe, fatal disease in animal models. J Infect Dis (2011) 1.98
Multiple SVM-RFE for gene selection in cancer classification with expression data. IEEE Trans Nanobioscience (2005) 1.91
rpoB Gene mutations and molecular characterization of rifampin-resistant Mycobacterium tuberculosis isolates from Shandong Province, China. J Clin Microbiol (2006) 1.68
Expression of mTOR signaling pathway markers in prostate cancer progression. Prostate (2006) 1.57
Multicenter evaluation of an investigational prostate cancer methylation assay. J Urol (2009) 1.56
Melanoma-specific marker expression in skin biopsy tissues as a tool to facilitate melanoma diagnosis. J Invest Dermatol (2010) 1.52
Expression of nuclear factor-kappa B and I kappa B alpha proteins in prostatic adenocarcinomas: correlation of nuclear factor-kappa B immunoreactivity with disease recurrence. Clin Cancer Res (2004) 1.49
Oligodeoxyribonucleotide probe accessibility on a three-dimensional DNA microarray surface and the effect of hybridization time on the accuracy of expression ratios. BMC Biotechnol (2003) 1.49
Histone deacetylase inhibitor depsipeptide activates silenced genes through decreasing both CpG and H3K9 methylation on the promoter. Mol Cell Biol (2008) 1.48
Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study. J Clin Oncol (2007) 1.46
Bilateral stereotactic radiofrequency amygdalohippocampectomy for a patient with bilateral temporal lobe epilepsy. Epilepsia (2013) 1.40
Mouse relapse model of Clostridium difficile infection. Infect Immun (2011) 1.36
The role of alpha 6 integrin in prostate cancer migration and bone pain in a novel xenograft model. PLoS One (2008) 1.31
Acetylation of FoxO1 activates Bim expression to induce apoptosis in response to histone deacetylase inhibitor depsipeptide treatment. Neoplasia (2009) 1.27
A highly reproducible, linear, and automated sample preparation method for DNA microarrays. Genome Res (2002) 1.27
Operational research to inform a sub-national surveillance intervention for malaria elimination in Solomon Islands. Malar J (2012) 1.25
Membrane type-1-matrix metalloproteinase expressed by prostate carcinoma cells cleaves human laminin-5 beta3 chain and induces cell migration. Cancer Res (2003) 1.25
Methylation of SUV39H1 by SET7/9 results in heterochromatin relaxation and genome instability. Proc Natl Acad Sci U S A (2013) 1.24
Phase II study of erlotinib in patients with locally advanced or metastatic papillary histology renal cell cancer: SWOG S0317. J Clin Oncol (2009) 1.21
Methyltransferase Set7/9 regulates p53 activity by interacting with Sirtuin 1 (SIRT1). Proc Natl Acad Sci U S A (2011) 1.17
Development of a clinically feasible molecular assay to predict recurrence of stage II colon cancer. J Mol Diagn (2008) 1.17
KRAS and BRAF mutation status in circulating colorectal tumor cells and their correlation with primary and metastatic tumor tissue. Int J Cancer (2013) 1.16
Extracellular alpha 6 integrin cleavage by urokinase-type plasminogen activator in human prostate cancer. Exp Cell Res (2004) 1.16
Biogenesis, structure, and immune-suppressive effects of virus-like particles of a Drosophila parasitoid, Leptopilina victoriae. J Insect Physiol (2005) 1.16
Phase 3 clinical trial investigating the effect of selenium supplementation in men at high-risk for prostate cancer. Prostate (2012) 1.15
Integrin alpha6 cleavage: a novel modification to modulate cell migration. Exp Cell Res (2007) 1.14
Role of c-Myc in intestinal tumorigenesis of the ApcMin/+ mouse. Cancer Biol Ther (2006) 1.14
Different phenotypes in human prostate cancer: alpha6 or alpha3 integrin in cell-extracellular adhesion sites. Neoplasia (2002) 1.13
Prevalence of nontuberculous mycobacteria infection, China, 2004-2009. Emerg Infect Dis (2012) 1.11
Anticancer antibodies. Am J Clin Pathol (2003) 1.11
Regulatory effects of hydrogen sulfide on IL-6, IL-8 and IL-10 levels in the plasma and pulmonary tissue of rats with acute lung injury. Exp Biol Med (Maywood) (2008) 1.08
A quantitative reverse transcriptase-polymerase chain reaction assay to identify metastatic carcinoma tissue of origin. J Mol Diagn (2006) 1.08
Aurora-A over-expression in high-grade PIN lesions and prostate cancer. Prostate (2005) 1.06
The laminin binding integrin alpha6beta1 in prostate cancer perineural invasion. J Cell Physiol (2010) 1.06
Prognostic gene expression signatures can be measured in tissues collected in RNAlater preservative. J Mol Diagn (2006) 1.06
Effect of aspirin, other NSAIDs, and statins on PSA and PSA velocity. Prostate (2010) 1.06
Angiogenesis and neovascularization associated with extracellular matrix-modified porous implants. J Biomed Mater Res (2002) 1.04
Membrane-type 1 matrix metalloproteinase is regulated by sp1 through the differential activation of AKT, JNK, and ERK pathways in human prostate tumor cells. Neoplasia (2007) 1.04
Identifying sources and assessing potential risk of heavy metals in soils from direct exposure to children in a mine-impacted city, Changsha, China. J Environ Qual (2010) 1.03
Randomized, double-blind, placebo-controlled trial of polyphenon E in prostate cancer patients before prostatectomy: evaluation of potential chemopreventive activities. Cancer Prev Res (Phila) (2011) 1.02
Membrane type 1 matrix metalloprotease cleaves laminin-10 and promotes prostate cancer cell migration. Neoplasia (2005) 1.01
Quantifying factors for the success of stratified medicine. Nat Rev Drug Discov (2011) 1.00
Laboratory-based surveillance of extensively drug-resistant tuberculosis, China. Emerg Infect Dis (2011) 0.99
Development of a multiplexed urine assay for prostate cancer diagnosis. Clin Chem (2008) 0.99
Overexpression of tumor vascular endothelial growth factor A may portend an increased likelihood of progression in a phase II trial of bevacizumab and erlotinib in resistant ovarian cancer. Clin Cancer Res (2010) 0.99
HDAC inhibitors act with 5-aza-2'-deoxycytidine to inhibit cell proliferation by suppressing removal of incorporated abases in lung cancer cells. PLoS One (2008) 0.98
Cross-validation of murine UV signal transduction pathways in human skin. Photochem Photobiol (2008) 0.97
Retracted Mutations in the G-quadruplex silencer element and their relationship to c-MYC overexpression, NM23 repression, and therapeutic rescue. Proc Natl Acad Sci U S A (2004) 0.97
Early responses of insulin signaling to high-carbohydrate and high-fat overfeeding. Nutr Metab (Lond) (2009) 0.95
Fibroblast growth factor-1 induced promatrilysin expression through the activation of extracellular-regulated kinases and STAT3. Neoplasia (2002) 0.95
Permutation - based statistical tests for multiple hypotheses. Source Code Biol Med (2008) 0.95
Region-specific detection of neuroblastoma loss of heterozygosity at multiple loci simultaneously using a SNP-based tag-array platform. Genome Res (2005) 0.95
Expression profiling with oligonucleotide arrays: technologies and applications for neurobiology. Neurochem Res (2002) 0.94
Potential health risk of arsenic and cadmium in groundwater near Xiangjiang River, China: a case study for risk assessment and management of toxic substances. Environ Monit Assess (2010) 0.93
Proliferating cell nuclear antigen is protected from degradation by forming a complex with MutT Homolog2. J Biol Chem (2009) 0.92
Integration of genomic data for inferring protein complexes from global protein-protein interaction networks. IEEE Trans Syst Man Cybern B Cybern (2008) 0.91
90K/Mac-2 binding protein is expressed in prostate cancer and induces promatrilysin expression. Prostate (2006) 0.91
5-Aza-2'-deoxycytidine reactivates gene expression via degradation of pRb pocket proteins. FASEB J (2011) 0.90
Ingestion risks of metals in groundwater based on TIN model and dose-response assessment - A case study in the Xiangjiang watershed, central-south China. Sci Total Environ (2010) 0.89
GRIP: A web-based system for constructing Gold Standard datasets for protein-protein interaction prediction. Source Code Biol Med (2009) 0.89
Fibroblast growth factor-1 transcriptionally induces membrane type-1 matrix metalloproteinase expression in prostate carcinoma cell line. Prostate (2004) 0.89
Antibody-based therapeutics in oncology. Expert Rev Anticancer Ther (2003) 0.88
Laminin alpha-1, alpha-3, and alpha-5 chain expression in human prepubertal [correction of prepubetal] benign prostate glands and adult benign and malignant prostate glands. Prostate (2003) 0.87
Anterior gradient 2 (AGR2): blood-based biomarker elevated in metastatic prostate cancer associated with the neuroendocrine phenotype. Prostate (2012) 0.87
Genome of Helicobacter pylori strain XZ274, an isolate from a tibetan patient with gastric cancer in China. J Bacteriol (2012) 0.85
A large scale comparative genomic analysis reveals insertion sites for newly acquired genomic islands in bacterial genomes. BMC Microbiol (2011) 0.84
Participatory research to design a novel telehealth system to support the night-time needs of people with dementia: NOCTURNAL. Int J Environ Res Public Health (2013) 0.84
Drug-induced hypothermia in stroke models: does it always protect? CNS Neurol Disord Drug Targets (2013) 0.83
Expressions of CK-19, NF-kappaB, E-cadherin, beta-catenin and EGFR as diagnostic and prognostic markers by immunohistochemical analysis in thyroid carcinoma. J Exp Ther Oncol (2011) 0.83
Stimulated endothelial cell adhesion and angiogenesis with laminin-5 modification of expanded polytetrafluoroethylene. Tissue Eng (2005) 0.83
The Nucleocapsid Protein of Coronaviruses Acts as a Viral Suppressor of RNA Silencing in Mammalian Cells. J Virol (2015) 0.83
A machine learning approach to assessing gait patterns for Complex Regional Pain Syndrome. Med Eng Phys (2011) 0.83
Human laminin-5 and laminin-10 mediated gene expression of prostate carcinoma cells. Prostate (2006) 0.83
Design and activity of a murine and humanized anti-CEACAM6 single-chain variable fragment in the treatment of pancreatic cancer. Cancer Res (2009) 0.83
Serum protein acidic and rich in cysteine (SPARC) as a prognostic marker in soft tissue sarcomas. Clin Sarcoma Res (2014) 0.82
Controllable synthesis of hierarchical porous Fe3O4 particles mediated by poly(diallyldimethylammonium chloride) and their application in arsenic removal. ACS Appl Mater Interfaces (2013) 0.82
Predictive integration of gene functional similarity and co-expression defines treatment response of endothelial progenitor cells. BMC Syst Biol (2011) 0.82
Human Cell Surface Receptors as Molecular Imaging Candidates for Metastatic Prostate Cancer. Open Prost Cancer J (2009) 0.82
ERK crosstalks with 4EBP1 to activate cyclin D1 translation during quinol-thioether-induced tuberous sclerosis renal cell carcinoma. Toxicol Sci (2011) 0.81
Selenium and selenomethionine levels in prostate cancer patients. Cancer Detect Prev (2004) 0.81
Differential localization of MT1-MMP in human prostate cancer tissue: role of IGF-1R in MT1-MMP expression. Prostate (2008) 0.81
iGAIT: an interactive accelerometer based gait analysis system. Comput Methods Programs Biomed (2012) 0.81
MiR-129 regulates MMP9 to control metastasis of non-small cell lung cancer. Tumour Biol (2015) 0.80
Detection of protein complexes from affinity purification/mass spectrometry data. BMC Syst Biol (2012) 0.80
Factors associated with delayed tuberculosis diagnosis in China. Eur J Public Health (2012) 0.80
Application of eigenmode in the adaptive optics system based on a micromachined membrane deformable mirror. Appl Opt (2006) 0.79
Systems-based biological concordance and predictive reproducibility of gene set discovery methods in cardiovascular disease. J Biomed Inform (2011) 0.79
Morphological changes of ricin toxin-induced apoptosis in human cervical cancer cells. Toxicol Ind Health (2011) 0.79
A knowledge-driven probabilistic framework for the prediction of protein-protein interaction networks. Comput Biol Med (2010) 0.79
Altered spatial learning and delay discounting in a rat model of human third trimester binge ethanol exposure. Behav Pharmacol (2012) 0.79